Voclosporin
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Voclosporin |
| DrugBank ID | DB11693 |
| Brand Names (EU) | Lupkynis |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 95.42% |
Approved Indication (EMA)
Lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | primary release disorder of platelets | 95.42% | DL |
| 2 | Glanzmann thrombasthenia | 94.87% | DL |
| 3 | pseudo-von Willebrand disease | 94.57% | DL |
| 4 | dermatitis | 94.18% | DL |
| 5 | renal osteodystrophy | 94.16% | DL |
| 6 | exanthem (disease) | 93.88% | DL |
| 7 | severe nonproliferative diabetic retinopathy | 93.40% | DL |
| 8 | neonatal dermatomyositis | 92.94% | DL |
| 9 | acrodermatitis chronica atrophicans | 92.91% | DL |
| 10 | non-renal secondary hyperparathyroidism | 92.86% | DL |
| 11 | amyopathic dermatomyositis | 92.71% | DL |
| 12 | impaired renal function disease | 92.68% | DL |
| 13 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | 92.05% | DL |
| 14 | indolent plasma cell myeloma | 91.84% | DL |
| 15 | hyperparathyroidism, transient neonatal | 91.66% | DL |
| 16 | acne keloid | 91.65% | DL |
| 17 | hydroa vacciniforme, familial | 91.62% | DL |
| 18 | bronchitis | 91.56% | DL |
| 19 | plasma cell myeloma | 91.33% | DL |
| 20 | ulcerative colitis (disease) | 91.06% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.